Plain-English translation of NCT06967194 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether metoprolol, a medication that slows your heart rate and lowers blood pressure, can help patients who have just had a severe heart attack (called STEMI) and are showing early signs of shock. Half of the participants will receive the medication, and half will receive a placebo (a pill with no active ingredient). The study will follow you closely for 72 hours to see if the medication helps prevent your condition from getting worse.
After a severe heart attack, some patients develop cardiogenic shock—a life-threatening condition where the heart cannot pump blood effectively. Doctors are unsure whether giving this medication early can safely help stabilize these patients and prevent them from deteriorating further.
You likely qualify if…
You likely don't qualify if…
After you are admitted to the cardiac intensive care unit with a heart attack, you will be randomly assigned to receive either the medication or a placebo twice daily. You will stay in the ICU for continuous monitoring of your heart rate, blood pressure, and blood lactate levels for 72 hours or until your condition changes significantly, whichever comes first. Your doctors will check on you every 24 hours and may stop the study medication if your condition improves enough to safely receive standard treatment.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Israel